Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration
Roivant Sciences (ROIV.O) and Pfizer Inc (PFE.N) on Thursday announced the creation of a new unit to develop RVT-3101, the drugmakers’ treatment for ulcerative colitis.